Equity Research, Broker Reports, and media content on ILIKA PLC

  • Access the latest forecasts, broker valuations, multiples, and video content from the city about ILIKA PLC
  • See live updates from analysts, company announcements, and other news in a personalised/single dashboard

Research, Charts & Company Announcements

Research Tree provides access to ongoing research coverage, media content and regulatory news on ILIKA PLC. We currently have 29 research reports from 4 professional analysts.

Open
47.5
Volume
0.0m
Range
45.0/47.5
Market Cap
36m
52 Week
41.2/74.5
Date Source Announcement
23Mar17 07:00 RNS Patent grant for solid-state batteries in USA
17Mar17 18:25 RNS Replacement: Trading update
17Mar17 07:00 RNS Trading update
14Mar17 07:00 RNS Collaboration with Galvani Bioelectronics
09Mar17 07:00 RNS Toyota Funds Collaboration with Ilika
10Feb17 09:18 RNS Holding(s) in Company
02Feb17 07:00 RNS Materials development grant for Hard Disk Drives
  • Frequency of research reports

     

  • Research reports on

    ILIKA PLC

  • Providers covering

    ILIKA PLC

Latest Content

View the latest research, videos, and podcasts for this company.

Ilika enters £1m bioelectronics deal with GSK and Verily Life Sciences partnership company Galvani Bioelectronics

  • 14 Mar 17

This morning’s announcement from Ilika, although relatively modest in initial top line impact, has significant commercial implications in the medium to longer term. Galvani was established to advance bioelectronic medicine, an emerging scientific field aimed at using tiny implantable devices to control electrical signals in nerves to treat a range of debilitating chronic diseases. Galvani combines GSK’s world-leading drug discovery and disease biology expertise, with Verily’s expertise in the miniaturisation of low-power electronic devices, data analytics and software development for clinical applications. Veriliy – formerly Google Life Sciences – was set up by Google founders Larry Page and Sergey Brin for the advancement of life sciences. Solid-state battery technology is really currently the only existing low-power source choice for intra-body bioelectronic medical applications for the following reasons: i. There is no potential for the leakage of harmful liquid electrolytes into the human body chemistry. ii. Solid-state battery chemistry can be miniaturized to a further extent than liquid based chemistries, due to negligible leakage currents and the capacity to maintain much smaller charges for much longer times. Ilika’s Stereax™ solid-state battery platform has been selected for the development effort. For bioelectronics applications of this nature batteries are charged wirelessly in situ using magnetic fields in a process known as nearfield charging. The first stage of this development is being funded by Innovate UK and the Medical Research Council.